Filtered By:
Condition: Alcoholism
This page shows you your search results in order of date. This is page number 13.
Order by Relevance | Date
Total 52199 results found since Jan 2013.
Non-alcoholic fatty liver disease: Immunological mechanisms and current treatments
World J Gastroenterol. 2023 Aug 28;29(32):4831-4850. doi: 10.3748/wjg.v29.i32.4831.ABSTRACTNon-alcoholic fatty liver disease (NAFLD) causes significant global disease burden and is a leading cause of mortality. NAFLD induces a myriad of aberrant changes in hepatocytes at both the cellular and molecular level. Although the disease spectrum of NAFLD is widely recognised, the precise triggers for disease progression are still to be fully elucidated. Furthermore, the propagation to cirrhosis is poorly understood. Whilst some progress in terms of treatment options have been explored, an incomplete understanding of the hepatic c...
Source: World Journal of Gastroenterology : WJG - September 13, 2023 Category: Gastroenterology Authors: Lucy Petagine Mohammed Gulrez Zariwala Vinood B Patel Source Type: research
Diabetes and non-alcoholic fatty liver disease: a bittersweet symphony
Med J Aust. 2023 Sep 12. doi: 10.5694/mja2.52106. Online ahead of print.NO ABSTRACTPMID:37700569 | DOI:10.5694/mja2.52106
Source: Med J Aust - September 13, 2023 Category: General Medicine Authors: Daniel Clayton-Chubb Stuart K Roberts Source Type: research
Non-alcoholic fatty liver disease: Immunological mechanisms and current treatments
World J Gastroenterol. 2023 Aug 28;29(32):4831-4850. doi: 10.3748/wjg.v29.i32.4831.ABSTRACTNon-alcoholic fatty liver disease (NAFLD) causes significant global disease burden and is a leading cause of mortality. NAFLD induces a myriad of aberrant changes in hepatocytes at both the cellular and molecular level. Although the disease spectrum of NAFLD is widely recognised, the precise triggers for disease progression are still to be fully elucidated. Furthermore, the propagation to cirrhosis is poorly understood. Whilst some progress in terms of treatment options have been explored, an incomplete understanding of the hepatic c...
Source: World Journal of Gastroenterology : WJG - September 13, 2023 Category: Gastroenterology Authors: Lucy Petagine Mohammed Gulrez Zariwala Vinood B Patel Source Type: research
Drug use among medical students in S ão Paulo, Brazil: a cross-sectional study during the coronavirus disease 2019 pandemic
CONCLUSION: The prevalence of substance use was high in this population and increased from the basic to the clinical cycle. The COVID-19 pandemic may have affected the frequency of drug use and prevalence estimates.PMID:37703121 | PMC:PMC10495101 | DOI:10.1590/1516-3180.2022.0493.R1.150623
Source: Sao Paulo Medical Journal - September 13, 2023 Category: General Medicine Authors: Pedro Lemos-Santos Lukas Blumrich Jordi Blanes Debia Jo ão Mauricio Castaldelli-Maia Paulo Jeng Chian Suen Andr é Malbergier Source Type: research
Non-alcoholic fatty liver disease: Immunological mechanisms and current treatments
World J Gastroenterol. 2023 Aug 28;29(32):4831-4850. doi: 10.3748/wjg.v29.i32.4831.ABSTRACTNon-alcoholic fatty liver disease (NAFLD) causes significant global disease burden and is a leading cause of mortality. NAFLD induces a myriad of aberrant changes in hepatocytes at both the cellular and molecular level. Although the disease spectrum of NAFLD is widely recognised, the precise triggers for disease progression are still to be fully elucidated. Furthermore, the propagation to cirrhosis is poorly understood. Whilst some progress in terms of treatment options have been explored, an incomplete understanding of the hepatic c...
Source: World Journal of Gastroenterology - September 13, 2023 Category: Gastroenterology Authors: Lucy Petagine Mohammed Gulrez Zariwala Vinood B Patel Source Type: research
Drug use among medical students in S ão Paulo, Brazil: a cross-sectional study during the coronavirus disease 2019 pandemic
CONCLUSION: The prevalence of substance use was high in this population and increased from the basic to the clinical cycle. The COVID-19 pandemic may have affected the frequency of drug use and prevalence estimates.PMID:37703121 | PMC:PMC10495101 | DOI:10.1590/1516-3180.2022.0493.R1.150623
Source: Sao Paulo Medical Journal - September 13, 2023 Category: General Medicine Authors: Pedro Lemos-Santos Lukas Blumrich Jordi Blanes Debia Jo ão Mauricio Castaldelli-Maia Paulo Jeng Chian Suen Andr é Malbergier Source Type: research
Non-alcoholic fatty liver disease: Immunological mechanisms and current treatments
World J Gastroenterol. 2023 Aug 28;29(32):4831-4850. doi: 10.3748/wjg.v29.i32.4831.ABSTRACTNon-alcoholic fatty liver disease (NAFLD) causes significant global disease burden and is a leading cause of mortality. NAFLD induces a myriad of aberrant changes in hepatocytes at both the cellular and molecular level. Although the disease spectrum of NAFLD is widely recognised, the precise triggers for disease progression are still to be fully elucidated. Furthermore, the propagation to cirrhosis is poorly understood. Whilst some progress in terms of treatment options have been explored, an incomplete understanding of the hepatic c...
Source: World Journal of Gastroenterology - September 13, 2023 Category: Gastroenterology Authors: Lucy Petagine Mohammed Gulrez Zariwala Vinood B Patel Source Type: research
Zero alcohol, but not zero risk?
Aust N Z J Psychiatry. 2023 Sep 13:48674231200399. doi: 10.1177/00048674231200399. Online ahead of print.NO ABSTRACTPMID:37702206 | DOI:10.1177/00048674231200399
Source: The Australian and New Zealand Journal of Psychiatry - September 13, 2023 Category: Psychiatry Authors: Anthony Hew Shalini Arunogiri Source Type: research
Emerging therapeutic options for non-alcoholic fatty liver disease: A systematic review
CONCLUSION: The data analyzed in this review showed clinically significant improvement in individual histological features of NAFLD in both animal and human trials for all four classes, as well as good safety profiles (P < 0.05). We believe this compilation of information will have positive clinical implications in obtaining an FDA-approved therapy for NAFLD.PMID:37701920 | PMC:PMC10494562 | DOI:10.4254/wjh.v15.i8.1001
Source: World Journal of Hepatology - September 13, 2023 Category: Gastroenterology Authors: Jasmine Tidwell Natalie Balassiano Anjiya Shaikh Mahmoud Nassar Source Type: research
Drug use among medical students in S ão Paulo, Brazil: a cross-sectional study during the coronavirus disease 2019 pandemic
CONCLUSION: The prevalence of substance use was high in this population and increased from the basic to the clinical cycle. The COVID-19 pandemic may have affected the frequency of drug use and prevalence estimates.PMID:37703121 | PMC:PMC10495101 | DOI:10.1590/1516-3180.2022.0493.R1.150623
Source: Sao Paulo Medical Journal - September 13, 2023 Category: General Medicine Authors: Pedro Lemos-Santos Lukas Blumrich Jordi Blanes Debia Jo ão Mauricio Castaldelli-Maia Paulo Jeng Chian Suen Andr é Malbergier Source Type: research
Zero alcohol, but not zero risk?
Aust N Z J Psychiatry. 2023 Sep 13:48674231200399. doi: 10.1177/00048674231200399. Online ahead of print.NO ABSTRACTPMID:37702206 | DOI:10.1177/00048674231200399
Source: The Australian and New Zealand Journal of Psychiatry - September 13, 2023 Category: Psychiatry Authors: Anthony Hew Shalini Arunogiri Source Type: research
Emerging therapeutic options for non-alcoholic fatty liver disease: A systematic review
CONCLUSION: The data analyzed in this review showed clinically significant improvement in individual histological features of NAFLD in both animal and human trials for all four classes, as well as good safety profiles (P < 0.05). We believe this compilation of information will have positive clinical implications in obtaining an FDA-approved therapy for NAFLD.PMID:37701920 | PMC:PMC10494562 | DOI:10.4254/wjh.v15.i8.1001
Source: World Journal of Hepatology - September 13, 2023 Category: Gastroenterology Authors: Jasmine Tidwell Natalie Balassiano Anjiya Shaikh Mahmoud Nassar Source Type: research
